CellWell record HH-539926
Abstract PS4-07-16: Epigenetic Reactivation of estrogen receptor beta Enhances Antitumor Activity of a Novel estrogen receptor beta agonist CIDD-0149897 in Triple-Negative Breast Cancer
U. Pratap; M. Mahajan; K. Nassar; T. Adeniran; N. Karinel; G. Sareddy; N. Mukherjee; S. Viswanadhapalli; S. McHardy; A. Brenner; R. Vadlamudi
Clinical Cancer Research ยท 2026
In plain language
A novel estrogen receptor beta agonist combined with HDAC inhibitors synergistically reduced proliferation of triple-negative breast cancer cells and tumor growth in mouse models.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-539926
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.